Sunshine Pharmaceutical Industry: Net profit increase by about 80.1% to 93.9% compared to 2025.

Sens Pharma announced that in the financial year 2025, the group is expected to record revenue of approximately 7.7 billion to 7.8 billion yuan, representing an increase of approximately 16.0% to 17.6% compared to the revenue of approximately 6.635 billion yuan in the year ending on December 31, 2024. The group is expected to record profit attributable to equity shareholders of the company of approximately 1.3 billion to 1.4 billion yuan in the financial year 2025, representing an increase of approximately 80.1% to 93.9% compared to the restated profit attributable to equity shareholders of the company of approximately 722 million yuan in the financial year 2024.